Meeting
2011 ASCO Annual Meeting
Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first‑line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS).
Authors
S. Siena
Ospedale Niguarda Ca' Granda, Milan, Italy
S. Siena , J. Cassidy , J. Tabernero , R. L. Burkes , M. E. Barugel , Y. Humblet , D. Cunningham , F. Xu , K. Krishnan , J. Douillard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00364013
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3567^)
Abstract #
3567^
Poster Bd #
13G
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
First Author: Timothy Jay Price
Poster
2016 Gastrointestinal Cancers Symposium
An open label, randomized phase 3 trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
First Author: Tae Won Kim
Poster
2015 ASCO Annual Meeting
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Marc Peeters
Poster
2015 Gastrointestinal Cancers Symposium
Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Timothy Jay Price